Navigation Links
EmergingMed Granted Patent

NEW YORK, June 3 /PRNewswire/ -- The U.S. Patent Office issued Patent No. 7,711,580, A System and Method for Matching Patients With Clinical Trials, to EmergingMed on May 4, 2010.

The patent covers a system and method for matching patients with clinical trials and particular trial sites, prequalifying patients for clinical trials and trial sites, and providing information to patients to allow them to inform themselves about available clinical trials and trial sites.

"The growth of targeted therapies as well as molecular diagnostics and gene expression profiling raises the complexity of finding clinical trials and personalized health information quickly, accurately, and confidentially," says Dr. Karen Moffitt of Florida Cancer Trials.  "EmergingMed's system simultaneously solves this problem for Florida's physicians and investigators, and most importantly our patients."

"AstraZeneca understands how challenging it can be for a patient or caregiver to navigate the multitude of information sources that exist for oncology clinical trials, let alone to identify trials that may be an appropriate match for themselves or a loved one," said Edward Mannello, Director of Clinical Study Recruitment, AstraZeneca. "For that reason, AstraZeneca has collaborated with EmergingMed because of the unique service they can provide to patients--a customized tool that helps them find trials that may be best matched to their specific needs."

"LIVESTRONG is proud to partner with EmergingMed on our SurvivorCare program," added Andy Miller, Executive Vice President of Mission for the Lance Armstrong Foundation.  "EmergingMed is instrumental in providing comprehensive support to people affected by cancer through their unique clinical trials education and matching program, their commitment to the cancer community, and their ability to respond to the needs of those affected by cancer."  

EmergingMed's phone and web-based matching system is featured by more than 50 patient advocacy organizations, pharmaceutical and biotech companies, and medical centers including Lance Armstrong Foundation, Pfizer, Genentech, AstraZeneca, EMD Serono, Enzon, CarisMPI, Ohio State University, the State of Florida, and POETIC.

"Trial sponsors and research sites utilize EmergingMed's customized solutions to find targeted patient populations, to ensure routine prescreening of all patients, and to analyze the suitability of their clinical trials for their specific patient populations," added Courtney Hudson, CEO.  "Our long-term follow-up with patients allows us to track outcomes, identify barriers, and empower patients to consider clinical trials each time a treatment decision is needed."  

EmergingMed said that although it will vigorously protect its intellectual property rights, it is seeking to broadly distribute its matching services beyond oncology to include other disease areas.

About EmergingMed

EmergingMed provides personalized clinical trial matching, referral support, education and long-term follow-up with patients on behalf of patient advocacy organizations, medical centers, pharmaceutical & biotech companies, and the State of Florida. Founded in 2000, EmergingMed has offices in New York, NY and Durham, NC.   For more information, call 1-877-601-8601 ext. 230 or write to

SOURCE EmergingMed
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
3. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
4. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
5. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
8. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
9. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
10. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
11. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):